Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Expands Smoking Cessation Line As Private Label Burns Up Category

Executive Summary

Perrigo launches a private label version of Nicorette White Ice Mint Gum, a product it says generates nearly $80m in annual sales. Private label leads the smoking cessation category, with GSK the leading branded marketer.

You may also be interested in...

Perrigo Starts Branded Consumer Product Rescue Mission In Belgium

Perrigo is restructuring its OTC drug and nutritional product businesses in Belgium – Omega Pharma Belgium NV, Etixx NV and Biover NV – and expects changes will eliminate between 45 and 80 jobs.

In Brief

Novartis ships Excedrin Migraine; Perrigo will launch mini nicotine lozenges; Matrixx ups offer to buy ProPhase; Merck consolidates HQ in Summit, N.J.; NBTY expects at least 3% sales boost; FDA will hold risk communication meeting; more news In Brief.

FDA Gets Message In Congress' First Cannabis Policy Hearing: Deliver CBD Regulation

During first-ever congressional hearing on federal policies for lawful use of cannabis, House Energy and Commerce Health Subcommittee Chairwoman Anna Eschoo says with $2m appropriated to develop a regulation on CBD’s use in non-drug products during, FDA should deliver.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts